Program
aficamten
Also written as “Aficamten”, “BAY3723113” and “Aficamten (5 - 20 mg)”.
Its studies are mostly in Cardiomyopathy, Hypertrophic, led by 3 companies.
Drug pageAficamten: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cytokineticsits history only | 83 open or running | phase 3since Apr 9, 2021 | Dec 3, 2018 | Mar 2029phase 3 · NCT04848506 |
| Corxel Pharmaceuticals | 20 open or running | phase 3since Oct 25, 2023 | Mar 3, 2021 | none ahead |
| Bayerits history only | 11 open or running | phase 3since Jun 10, 2025 | Jun 10, 2025 | none ahead |
Also a collaborator on its studies: Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Corxel Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named aficamtenINNProposed as its International Nonproprietary Name in WHO's List 124 · before, BAY3723113
- Mar 3, 2021First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT04783766 · 28 enrolled · China
- Oct 25, 2023Phase 3 study in Cardiomyopathy, HypertrophicNCT06116968 · 40 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Corxel Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06116968Cardiomyopathy, Hypertrophic · China | 3 | Completed | Oct 20, 2025 | 40 |
| NCT04783766Cardiomyopathy, Hypertrophic · China | 1 | Completed | Aug 5, 2021 | 28 |
How it is read
Names in the registry
- “Aficamten”, 4 entries
- “BAY3723113”, 1 entry
- “Aficamten (5 - 20 mg)”, 1 entry
- “Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)”, 1 entry
- “Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)”, 1 entry
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.